Abstract
Idiopathic anaphylaxis involves episodes of anaphylaxis without a specific trigger. Management includes antihistamines and mast cell stabilizers, but some patients fail to respond to this treatment. Omalizumab, an anti-IgE monoclonal antibody, is not approved for treatment of idiopathic anaphylaxis, but has been used in patients with idiopathic anaphylaxis under concurrent diagnoses of allergic asthma or chronic idiopathic urticaria. We describe the clinical response to omalizumab in patients with idiopathic anaphylaxis without evidence of mast cell clonality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
